Literature DB >> 22895507

Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes.

A P Dane1, S J Wowro, S C Cunningham, I E Alexander.   

Abstract

Adeno-associated virus (AAV) vectors are highly efficient for liver-targeted gene delivery in murine models and show promise in early phase human clinical trials. This efficiency is capsid-dependent and was only achieved after discovery that the AAV2 vector genome could be trans-encapsidated into the capsids of other AAV serotypes. This confers novel host-vector biology and target tissue tropism. Optimal exploitation of the growing number of AAV vector pseudo-serotypes, however, requires detailed context-dependent characterisation of transduction performance. In this study, we compared the pattern and efficiency of gene delivery to the adult mouse liver following intraportal and intraperitoneal injection of vectors pseudo-serotyped with known hepatotropic capsids from AAV type 7, 8, 9 and rhesus 10. Vectors pseudo-serotyped with these hepatotropic capsids proved relatively efficient irrespective of administration route, with higher transgene expression in males despite equivalent vector genome delivery in females. Transgene expression was predominantly centrilobular in contrast to the AAV2 capsid, which gave a periportal pattern of expression. Most intriguingly, vector genome performance appeared to be delivery route-dependent, consistent with the possibility of in vivo capsid modification. These data not only inform the experimental use of AAV vectors, but also provide insight into novel aspects of host-vector biology requiring further focused analysis.

Entities:  

Mesh:

Year:  2012        PMID: 22895507     DOI: 10.1038/gt.2012.67

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

1.  In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.

Authors:  Dustin J Landau; Elizabeth Drake Brooks; Pablo Perez-Pinera; Hiruni Amarasekara; Adam Mefferd; Songtao Li; Andrew Bird; Charles A Gersbach; Dwight D Koeberl
Journal:  Mol Ther       Date:  2016-02-11       Impact factor: 11.454

2.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

3.  Transient suppression of hepatocellular replication in the mouse liver following transduction with recombinant adeno-associated virus.

Authors:  A P Dane; S C Cunningham; C Y Kok; G J Logan; I E Alexander
Journal:  Gene Ther       Date:  2015-07-30       Impact factor: 5.250

4.  Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice.

Authors:  Cindy Y Kok; Sharon C Cunningham; Kevin H Carpenter; Allison P Dane; Susan M Siew; Grant J Logan; Philip W Kuchel; Ian E Alexander
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

5.  Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions.

Authors:  Lei Xu; Pei Juan Lu; Chi-Hsien Wang; Elizabeth Keramaris; Chunping Qiao; Bin Xiao; Derek J Blake; Xiao Xiao; Qi Long Lu
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

6.  Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity.

Authors:  Nicole K Paulk; Katja Pekrun; Erhua Zhu; Sean Nygaard; Bin Li; Jianpeng Xu; Kirk Chu; Christian Leborgne; Allison P Dane; Annelise Haft; Yue Zhang; Feijie Zhang; Chris Morton; Marcus B Valentine; Andrew M Davidoff; Amit C Nathwani; Federico Mingozzi; Markus Grompe; Ian E Alexander; Leszek Lisowski; Mark A Kay
Journal:  Mol Ther       Date:  2017-09-25       Impact factor: 11.454

7.  Live cell imaging of cytosolic NADH/NAD+ ratio in hepatocytes and liver slices.

Authors:  Ricard Masia; William J McCarty; Carolina Lahmann; Jay Luther; Raymond T Chung; Martin L Yarmush; Gary Yellen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-10-12       Impact factor: 4.052

Review 8.  Vector engineering, strategies and targets in cancer gene therapy.

Authors:  Vijayata Singh; Nusrat Khan; Giridhara R Jayandharan
Journal:  Cancer Gene Ther       Date:  2021-04-15       Impact factor: 5.987

9.  Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy.

Authors:  Ida Luisa Rotundo; Alessio Lancioni; Marco Savarese; Luca D'Orsi; Michele Iacomino; Gerardo Nigro; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  Hum Gene Ther       Date:  2013-04-04       Impact factor: 5.695

10.  Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids.

Authors:  Marti Cabanes-Creus; Renina Gale Navarro; Sophia H Y Liao; Grober Baltazar; Matthieu Drouyer; Erhua Zhu; Suzanne Scott; Clement Luong; Laurence O W Wilson; Ian E Alexander; Leszek Lisowski
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.